Vor Biopharma's Promising Clinical Trials and Strategic Developments Merit a Buy Rating
Justin Walsh from JonesTrading reiterated a Buy rating on Vor Biopharma (VOR) with a $18.00 price target, citing promising data from the VBP101 trial treating AML with trem-cel and MYLOTARG, and strategic discussions with the FDA around year-end 2024. Vor Biopharma also progresses with the VBP301 trial and introduces a new preclinical asset, VADC45.
Highlighted Terms
Related News
Wedbush analysts maintain Outperform rating and $11.00 price target on Vor Biopharma Inc. (VOR:NASDAQ) following positive data from VBP101 study and initial PK results for VCAR33ALLO, with strategic focus on advancing trem-cel towards a pivotal trial and expanding pipeline with new VADC45 program.
Justin Walsh from JonesTrading reiterated a Buy rating on Vor Biopharma (VOR) with a $18.00 price target, citing promising data from the VBP101 trial treating AML with trem-cel and MYLOTARG, and strategic discussions with the FDA around year-end 2024. Vor Biopharma also progresses with the VBP301 trial and introduces a new preclinical asset, VADC45.